Fintel reports that on January 10, 2025, Cantor Fitzgerald initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a ...

Eric Johnston, Cantor Fitzgerald chief equity and macro strategist, joins 'Money Movers' to discuss Johnston's thesis for ...

Cantor Fitzgerald reiterated their overweight rating on shares of Hut 8 (NASDAQ:HUT – Free Report) in a report released on ...

Cantor Fitzgerald initiated coverage of Bright Minds Biosciences (DRUG) with an Overweight rating and no price target The company’s emerging ...

Incyte (NASDAQ:INCY – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at Cantor Fitzgerald ...

Cantor Fitzgerald, the Wall Street firm headed by President-elect Donald Trump’s pick to serve as Commerce Secretary, will pay a $6.75 million civil penalty after it was accused of breaking ...

The Securities and Exchange Commission (SEC) on Thursday charged Cantor Fitzgerald L.P., a global financial services firm ...

Equities research analysts at Cantor Fitzgerald increased their FY2024 EPS estimates for Alphabet in a research report issued on Tuesday, January 7th. Cantor Fitzgerald analyst D. Mathivanan now ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, ...

Cantor Equity Partners I, Inc. (Nasdaq: CEPO) (the "Company") announced today that it closed its initial public offering of 20,000,000 Class A ordinary shares at $10.00 per share. The shares began ...

Weakness in Cantor Fitzgerald High Income A's Process and People Pillar ratings limits this strategy to a Morningstar Medalist Rating of Negative. Our research team assigns Negative ratings to ...

Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The most substantial contributor to the rating is the parent firm's five-year risk-adjusted success ratio of 90%.